Astrocytoma, IDH-mutant, grade 2
MONDO:0956994An IDH-mutant anaplastic astrocytoma that is characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system.
2845 clinical trials for this condition and its sub-types, 18 tagged with Astrocytoma, IDH-mutant, grade 2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Experimental drug combo targets brain cancer metabolism
Disease control OngoingThis early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Brain tumor drug vorasidenib tested in everyday practice
Disease control OngoingThis study looks at how well the drug vorasidenib works and how safe it is for people with a slow-growing type of brain tumor called grade 2 astrocytoma or oligodendroglioma that has an IDH1 or IDH2 mutation. The study includes people aged 12 and older in China who are treated in…
Sponsor: Servier (Tianjin) Pharmaceutical Co. LTD. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for asian brain tumor patients: targeted pill slows cancer growth
Disease control OngoingThis study tests an experimental pill, vorasidenib, in Asian patients with a slow-growing but serious brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). About 57 participants will receive either the drug or a placebo to see if it delays tumor progre…
Phase 3 • Sponsor: Servier • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC